Keyword Analysis & Research: sorrento therapeutics

Keyword Analysis


Keyword CPC PCC Volume Score Length of keyword
sorrento therapeutics1.740.474253121
sorrento1.730.4266288
therapeutics0.940.25115212

Keyword Research: People who searched sorrento therapeutics also searched

Keyword CPC PCC Volume Score
sorrento therapeutics0.610.959471

Search Results related to sorrento therapeutics on Search Engine

  • Home - Sorrento Therapeutics

    sorrentotherapeutics.com

    https://sorrentotherapeutics.com/

    WEBSorrento Therapeutics - We apply cutting-edge science to create innovative therapies that will improve the lives of those who suffer from cancer, intractable pain and COVID-19

    DA: 100 PA: 9 MOZ Rank: 49

  • Sorrento Therapeutics, Inc. (SRNEQ) - Yahoo Finance

    yahoo.com

    https://finance.yahoo.com/quote/SRNEQ/

    WEB2 days ago · Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious...

    DA: 43 PA: 77 MOZ Rank: 99

  • Sorrento Therapeutics Announces Positive Phase 2a Clinical

    globenewswire.com

    https://www.globenewswire.com/news-release/2023/09/07/2739412/0/en/Sorrento-Therapeutics-Announces-Positive-Phase-2a-Clinical-Trial-Results-for-Resiniferatoxin-RTX-for-the-Treatment-of-Knee-Pain-in-Moderate-to-Severe-Osteoarthritis-of-the-Knee-OAK.html

    WEBSAN DIEGO, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento") announced today positive Phase 2a top-line clinical trial results for the RTX program.

    DA: 70 PA: 24 MOZ Rank: 95

  • Sorrento Therapeutics, Inc. (SRNE) - Yahoo Finance

    yahoo.com

    https://finance.yahoo.com/quote/SRNE/

    WEB22 hours ago · Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious...

    DA: 21 PA: 43 MOZ Rank: 69

  • Investor Relations - Sorrento Therapeutics, Inc.

    sorrentotherapeutics.com

    https://investors.sorrentotherapeutics.com/

    WEBCorporate Profile. Sorrento is a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease and COVID-19. Sorrento's multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such ...

    DA: 25 PA: 30 MOZ Rank: 17

  • Sorrento Therapeutics, Inc.'s Bankruptcy Court Approves Elective

    sorrentotherapeutics.com

    https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-therapeutics-incs-bankruptcy-court-approves-elective

    WEBSAN DIEGO, July 20, 2023 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, intractable pain, and infectious disease, today announced that, in connection with its ongoing chapter.

    DA: 71 PA: 10 MOZ Rank: 89

  • Sorrento Enters Into Merger Agreement to ... - Sorrento Therapeutics

    sorrentotherapeutics.com

    https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-enters-merger-agreement-acquire-late-stage-oncology

    WEBSAN DIEGO, April 05, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced the signing of a merger agreement pursuant to which Sorrento will acquire ACEA Therapeutics, Inc. (“ACEA”).

    DA: 21 PA: 11 MOZ Rank: 18

  • Sorrento Completes Acquisition of ACEA ... - Sorrento Therapeutics

    sorrentotherapeutics.com

    https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-completes-acquisition-acea-therapeutics-creating-major

    WEBSAN DIEGO, June 02, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today that it has completed the acquisition of ACEA Therapeutics Inc. (“ACEA”). The merger was completed on June 1, 2021 and at such time, ACEA became a wholly owned subsidiary of Sorrento.

    DA: 33 PA: 56 MOZ Rank: 28

  • Sorrento Therapeutics, Inc. Receives Court Approval for $75 …

    prnewswire.com

    https://www.prnewswire.com/news-releases/sorrento-therapeutics-inc-receives-court-approval-for-75-million-financing-in-chapter-11-case-301752426.html

    WEBSAN DIEGO, Feb. 21, 2023 /PRNewswire/ -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat...

    DA: 20 PA: 3 MOZ Rank: 58

  • Sorrento Therapeutics, Inc. Announces the Consummation of the

    yahoo.com

    https://finance.yahoo.com/news/sorrento-therapeutics-inc-announces-consummation-153800928.html

    WEBSAN DIEGO, Sept. 22, 2023 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento" or "Company"), a biopharmaceutical company dedicated to the development of life-saving therapeutics...

    DA: 69 PA: 11 MOZ Rank: 41